NCT05933525View on ClinicalTrials.gov

Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

July 1, 2024

Study Completion Date

December 30, 2024

Conditions
DiarrheaTravelers DiarrheaInfectious Diarrhea
Interventions
BIOLOGICAL

Travelan

6 Travelan tablets (1200mg) administered orally for 7 days

OTHER

Placebo

6 tablets of placebo (1200mg) administered orally for 7 days

Trial Locations (1)

21201

Pharmaron Clinical Pharmacology Center, Baltimore

Sponsors

Lead Sponsor

Immuron Ltd.
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Naval Medical Research Center

FED

lead

Immuron Ltd.

INDUSTRY

NCT05933525 - Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model | Biotech Hunter | Biotech Hunter